You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 18, November 12, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Medical Practice
 •Conflict of Interest
 •Medical Ethics
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Psychological Aspects of Gifts From Drug Companies

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Mr Dana and Dr Loewenstein1 stated that "Performing industry-supported research, physicians face an implicit demand for a positive finding to obtain further financial support." I have been responsible for several thousand registration trials, carried out in approximately 50 countries for 4 major pharmaceutical companies, and I have never known investigators to be selected on the basis of their results. Investigators are selected according to a number of criteria, including experience in conducting clinical trials, ability to recruit the type and number of patients needed in the agreed-upon time, the production of complete and accurate data, and an optimal clinical research infrastructure.

Furthermore, most trials involve several centers, so that the findings from any given center are statistically irrelevant and infrequently decide the outcome of a trial. It would be very difficult, if not impossible, to conduct a multicenter study including only investigators who produce positive findings. It . . . [Full Text of this Article]

Michael Tansey, MD
Competitive Drug Development Inc
Jersey City, NJ



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Psychological Aspects of Gifts From Drug Companies
Dana Katz, Peter Mansfield, Robert Goodman, Leonore Tiefer, and Jon Merz
JAMA. 2003;290(18):2404-2405.
EXTRACT | FULL TEXT  

Psychological Aspects of Gifts From Drug Companies
Michael S. Goldrich
JAMA. 2003;290(18):2405.
EXTRACT | FULL TEXT  

Psychological Aspects of Gifts From Drug Companies
Gary A. Tarshis
JAMA. 2003;290(18):2405.
EXTRACT | FULL TEXT  

Psychological Aspects of Gifts From Drug Companies
Louis Bergeron
JAMA. 2003;290(18):2406.
EXTRACT | FULL TEXT  

Psychological Aspects of Gifts From Drug Companies
Chris McCoy and Lauren Oshman
JAMA. 2003;290(18):2406.
EXTRACT | FULL TEXT  

Psychological Aspects of Gifts From Drug Companies—Reply
Jason Dana and George Loewenstein
JAMA. 2003;290(18):2406-2407.
EXTRACT | FULL TEXT  

A Social Science Perspective on Gifts to Physicians From Industry
Jason Dana and George Loewenstein
JAMA. 2003;290(2):252-255.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.